Condition: Chronic Kidney Diseases · Sponsor: Tor Biering-Sørensen
The purpose of this study is to investigate the effects of dapagliflozin on echocardiographic measures of cardiac structure and function in patients with chronic kidney disease.
This description comes directly from the study's public registry record.
Katja Vu Bartholdy, MD · +4531360232 · katja.vu.bartholdy@regionh.dk
Niklas Dyrby Johansen · +4520204794 · niklas.dyrby.johansen@regionh.dk
Always discuss trial participation with your own doctor first.
| Gentofte Hospital | Copenhagen, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05359263